AVM0703
Relapsed/Refractory Non-Hodgkin's Lymphoma and Leukemia
Key Facts
About AVM Biotechnology
AVM Biotechnology is a private, clinical-stage company advancing its lead asset, AVM0703, a novel immunomodulatory therapy. The drug is currently in a pivotal Phase 2 trial for relapsed/refractory non-Hodgkin's lymphoma and leukemia, with a compassionate use program also active. Founded and led by Dr. Theresa Deisher, the company focuses on leveraging a unique mechanism of immune cell mobilization to address cancers and autoimmune conditions with high unmet need.
View full company profileAbout AVM Biotechnology
AVM Biotechnology is a private, clinical-stage company advancing its lead asset, AVM0703, a novel immunomodulatory therapy. The drug is currently in a pivotal Phase 2 trial for relapsed/refractory non-Hodgkin's lymphoma and leukemia, with a compassionate use program also active. Founded and led by Dr. Theresa Deisher, the company focuses on leveraging a unique mechanism of immune cell mobilization to address cancers and autoimmune conditions with high unmet need.
View full company profileAbout AVM Biotechnology
AVM Biotechnology is a private, clinical-stage company advancing its lead asset, AVM0703, a novel immunomodulatory therapy. The drug is currently in a pivotal Phase 2 trial for relapsed/refractory non-Hodgkin's lymphoma and leukemia, with a compassionate use program also active. Founded and led by Dr. Theresa Deisher, the company focuses on leveraging a unique mechanism of immune cell mobilization to address cancers and autoimmune conditions with high unmet need.
View full company profile